A Phase I Study of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) in Patients With Advanced Cancers.

Trial Profile

A Phase I Study of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) in Patients With Advanced Cancers.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin; Sorafenib; Temsirolimus
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 12 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 14 Mar 2013 Planned number of patients changed from 140 to 180 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top